BT1 Stock Overview
A biotech company, focuses on developing clinical assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0057 |
| 52 Week High | €0.092 |
| 52 Week Low | €0.001 |
| Beta | -2.74 |
| 11 Month Change | -19.72% |
| 3 Month Change | 1.79% |
| 1 Year Change | -79.64% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| BT1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | -79.6% | -17.5% | 7.4% |
Return vs Industry: BT1 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: BT1 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| BT1 volatility | |
|---|---|
| BT1 Average Weekly Movement | 61.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BT1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BT1's weekly volatility has decreased from 94% to 61% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| BT1 fundamental statistics | |
|---|---|
| Market cap | €1.62m |
| Earnings (TTM) | -€7.44m |
| Revenue (TTM) | €2.87m |
0.6x
P/S Ratio-0.2x
P/E RatioIs BT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BT1 income statement (TTM) | |
|---|---|
| Revenue | €2.87m |
| Cost of Revenue | €0 |
| Gross Profit | €2.87m |
| Other Expenses | €10.31m |
| Earnings | -€7.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 100.00% |
| Net Profit Margin | -259.05% |
| Debt/Equity Ratio | -125.9% |
How did BT1 perform over the long term?
See historical performance and comparison